CA3092372A1 - Tolerogenic liposomes and methods of use thereof - Google Patents
Tolerogenic liposomes and methods of use thereof Download PDFInfo
- Publication number
- CA3092372A1 CA3092372A1 CA3092372A CA3092372A CA3092372A1 CA 3092372 A1 CA3092372 A1 CA 3092372A1 CA 3092372 A CA3092372 A CA 3092372A CA 3092372 A CA3092372 A CA 3092372A CA 3092372 A1 CA3092372 A1 CA 3092372A1
- Authority
- CA
- Canada
- Prior art keywords
- composition
- lipid
- liposomes
- ite
- unsaturated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862635376P | 2018-02-26 | 2018-02-26 | |
| US62/635,376 | 2018-02-26 | ||
| US201862755946P | 2018-11-05 | 2018-11-05 | |
| US62/755,946 | 2018-11-05 | ||
| PCT/US2019/019609 WO2019165436A1 (en) | 2018-02-26 | 2019-02-26 | Tolerogenic liposomes and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3092372A1 true CA3092372A1 (en) | 2019-08-29 |
Family
ID=67688562
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3092372A Pending CA3092372A1 (en) | 2018-02-26 | 2019-02-26 | Tolerogenic liposomes and methods of use thereof |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12178908B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3758682A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2021515037A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20200139679A (cg-RX-API-DMAC7.html) |
| CN (1) | CN112384204B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019225251A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3092372A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL276957B2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019165436A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021515037A (ja) | 2018-02-26 | 2021-06-17 | アントルクス,インコーポレーテッド | 寛容原性リポソーム及びその使用方法 |
| US10736847B2 (en) | 2018-07-03 | 2020-08-11 | Becton, Dickinson And Company | Inverting device for liposome preparation by centrifugation |
| EP3999054A4 (en) * | 2019-07-16 | 2023-07-26 | Antolrx, Inc. | IMMUNE TOLERANCE AGENTS AND POTENTIALIZERS |
| CN113740525A (zh) * | 2020-05-29 | 2021-12-03 | 中国药科大学 | 一种检测肾损伤标志物胱抑素c的方法 |
| US20230391783A1 (en) * | 2021-05-27 | 2023-12-07 | Shandong University | Compound containing 2,4-thiazole ring, preparation method therefor, and application thereof |
| WO2024026452A1 (en) | 2022-07-29 | 2024-02-01 | Repertoire Immune Medicines, Inc. | T cell epitopes associated with type 1 diabetes |
| WO2024110516A1 (en) * | 2022-11-23 | 2024-05-30 | Ahead Therapeutics, S.L. | Tolerogenic composition |
| WO2025072849A1 (en) | 2023-09-29 | 2025-04-03 | Repertoire Immune Medicines, Inc. | Mhc-presentable peptides associated with type 1 diabetes |
Family Cites Families (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8918616D0 (en) | 1989-08-15 | 1989-09-27 | Univ Glasgow | Herpes simplex virus type 1 mutant |
| US5849572A (en) | 1990-10-10 | 1998-12-15 | Regents Of The University Of Michigan | HSV-1 vector containing a lat promoter |
| US5804413A (en) | 1992-07-31 | 1998-09-08 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Herpes simplex virus strains for gene transfer |
| DE69435223D1 (de) | 1993-10-25 | 2009-09-03 | Canji Inc | Rekombinanter Adenoviren-Vektor und Verfahren zur Verwendung |
| GB9415319D0 (en) | 1994-07-29 | 1994-09-21 | Medical Res Council | HSV viral vector |
| US5846782A (en) | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
| US5801030A (en) | 1995-09-01 | 1998-09-01 | Genvec, Inc. | Methods and vectors for site-specific recombination |
| US5837511A (en) | 1995-10-02 | 1998-11-17 | Cornell Research Foundation, Inc. | Non-group C adenoviral vectors |
| US5849561A (en) | 1997-05-22 | 1998-12-15 | Cornell Research Foundation, Inc. | Method for the production of non-group C adenoviral vectors |
| EP1002119A1 (en) | 1997-07-31 | 2000-05-24 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Targeted hsv vectors |
| US6436392B1 (en) | 1998-05-20 | 2002-08-20 | University Of Iowa Research Foundation | Adeno-associated virus vectors |
| US6759237B1 (en) | 1998-11-05 | 2004-07-06 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same |
| US6562943B1 (en) * | 1999-04-21 | 2003-05-13 | Zycos, Inc. | Peptide epitopes recognized by disease promoting CD4+ T lymphocytes |
| US7465583B2 (en) | 2000-06-01 | 2008-12-16 | The University Of North Carolina At Chapel Hill | Duplexed parvovirus vectors |
| US7122181B2 (en) | 2000-12-19 | 2006-10-17 | Research Development Foundation | Lentiviral vector-mediated gene transfer and uses thereof |
| CA2448066A1 (en) | 2001-05-31 | 2002-12-12 | Chiron Corporation | Chimeric alphavirus replicon particles |
| US20070129307A1 (en) | 2001-06-22 | 2007-06-07 | The University Of British Columbia | Insulin epitopes for the treatment of type 1 diabetes |
| ATE527347T1 (de) | 2001-08-02 | 2011-10-15 | Inst Clayton De La Rech | Verfahren und zusammensetzungen im zusammenhang mit verbesserten lentivirusvektor- produktionssystemen |
| WO2003023026A1 (en) | 2001-09-06 | 2003-03-20 | Alphavax, Inc. | Alphavirus replicon vector systems |
| CA2462628C (en) | 2001-10-02 | 2019-08-20 | Institut Clayton De La Recherche | Restricted expression lentiviral vectors |
| DK2359869T3 (en) | 2001-12-17 | 2019-04-15 | Univ Pennsylvania | Sequences of adeno-associated virus (AAV) serotype 8, vectors containing these, and uses thereof |
| ES2348868T3 (es) | 2002-12-13 | 2010-12-16 | Genetix Pharmaceuticals Inc. | Vectores retrovirales terapeuticos para terapia genica. |
| US7510872B2 (en) | 2003-02-26 | 2009-03-31 | Nationwide Children's Hospital | Recombinant adeno-associated virus production |
| US7186699B2 (en) | 2003-06-03 | 2007-03-06 | Cell Genesys, Inc. | Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes |
| EP1486567A1 (en) | 2003-06-11 | 2004-12-15 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Improved adeno-associated virus (AAV) vector for gene therapy |
| WO2005038035A2 (en) | 2003-10-15 | 2005-04-28 | University Of Iowa Research Foundation | Methods for producing and using in vivo pseudotyped retroviruses |
| EP2573185A3 (en) | 2005-02-16 | 2013-06-05 | Lentigen Corporation | Lentiviral vectors and their use |
| KR20080052512A (ko) | 2005-05-23 | 2008-06-11 | 박신, 인크. | 아데노바이러스-무함유 재조합 아데노바이러스 벡터의 급속생산 |
| FI20050814A0 (fi) | 2005-08-11 | 2005-08-11 | Procollagen Oy | Menetelmä nivelreumassa muodostuvien kollageeniautovasta-aineiden havaitsemiseksi |
| EP1974044B1 (en) | 2005-12-12 | 2011-01-26 | CANJI, Inc. | Adenoviral expression vectors having an expression cassette in the e1 region and an inactivated e2b polymerase |
| GB0526211D0 (en) | 2005-12-22 | 2006-02-01 | Oxford Biomedica Ltd | Viral vectors |
| US20080026485A1 (en) | 2006-04-18 | 2008-01-31 | Wolfgang Hueber | Antibody profiling for determination of patient responsiveness |
| US7951925B2 (en) | 2006-05-25 | 2011-05-31 | Sangamo Biosciences, Inc. | Methods and compositions for gene inactivation |
| CA2669746C (en) | 2006-12-14 | 2017-05-16 | Dow Agrosciences Llc | Optimized non-canonical zinc finger proteins |
| US20100047256A1 (en) | 2007-01-25 | 2010-02-25 | Imperial Innovations Limited | Methods |
| ES2708856T3 (es) | 2007-08-03 | 2019-04-11 | Pasteur Institut | Vectores de transferencia de gen lentivírico y sus aplicaciones medicinales |
| ES2422291T3 (es) | 2007-10-31 | 2013-09-10 | Prec Biosciences Inc | Meganucleasas monocatenarias diseñadas racionalmente con secuencias de reconocimiento no palindrómicas |
| JP2011503232A (ja) | 2007-11-20 | 2011-01-27 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | 免疫応答の調節 |
| WO2009076292A2 (en) | 2007-12-07 | 2009-06-18 | Precision Biosciences, Inc. | Rationally-designed meganucleases with recognition sequences found in dnase hypersensitive regions of the human genome |
| WO2009114321A2 (en) | 2008-03-11 | 2009-09-17 | Precision Biosciencs, Inc. | Rationally-designed meganucleases for maize genome engineering |
| JP2011519266A (ja) | 2008-03-21 | 2011-07-07 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | 免疫反応の調節 |
| WO2009146179A1 (en) | 2008-04-15 | 2009-12-03 | University Of Iowa Research Foundation | Zinc finger nuclease for the cftr gene and methods of use thereof |
| EP2342321B1 (en) | 2008-09-17 | 2018-04-11 | Isogenis, Inc. | Construction of fully-deleted adenovirus-based gene delivery vectors and uses thereof |
| EA201100765A1 (ru) * | 2008-12-15 | 2012-04-30 | Бинд Биосаиэнсис | Наночастицы длительной циркуляции для замедленного высвобождения терапевтических средств |
| US8679837B2 (en) | 2009-04-02 | 2014-03-25 | University Of Florida Research Foundation, Inc. | Inducible system for highly efficient production of recombinant Adeno-associated virus (rAAV) vectors |
| WO2011036640A2 (en) | 2009-09-24 | 2011-03-31 | Cellectis | Meganuclease reagents of uses thereof for treating genetic diseases caused by frame shift/non sense mutations |
| EP2486137B1 (en) | 2009-10-05 | 2018-05-30 | Ya-Fang Mei | Replication-competent ad11p based viral vectors |
| US8956828B2 (en) | 2009-11-10 | 2015-02-17 | Sangamo Biosciences, Inc. | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
| PT2816112T (pt) | 2009-12-10 | 2018-11-20 | Univ Iowa State Res Found Inc | Modificação do adn modificada pelo efector tal |
| US9255259B2 (en) | 2010-02-09 | 2016-02-09 | Sangamo Biosciences, Inc. | Targeted genomic modification with partially single-stranded donor molecules |
| US8927514B2 (en) | 2010-04-30 | 2015-01-06 | City Of Hope | Recombinant adeno-associated vectors for targeted treatment |
| ES2685611T3 (es) | 2011-02-14 | 2018-10-10 | The Children's Hospital Of Philadelphia | Vector VAA8 mejorado con una actividad funcional aumentada y métodos de utilización del mismo |
| US20140155469A1 (en) | 2011-04-19 | 2014-06-05 | The Research Foundation Of State University Of New York | Adeno-associated-virus rep sequences, vectors and viruses |
| CN107320734A (zh) * | 2011-04-29 | 2017-11-07 | 西莱克塔生物科技公司 | 从合成纳米载体中控制释放免疫抑制剂 |
| KR101873447B1 (ko) | 2011-06-22 | 2018-07-03 | 삼성디스플레이 주식회사 | 신규한 화합물 및 이를 포함한 유기발광 소자 |
| EP2836226B1 (en) | 2012-02-24 | 2017-06-28 | Fred Hutchinson Cancer Research Center | Compositions and methods for the treatment of hemoglobinopathies |
| EP2638896A1 (en) * | 2012-03-14 | 2013-09-18 | Bioneer A/S | Cationic liposomal drug delivery system for specific targeting of human cd14+ monocytes in whole blood |
| JP2015527296A (ja) | 2012-03-26 | 2015-09-17 | アメリカ合衆国 | 哺乳動物細胞へのパッケージングされたrnaの新規の送達 |
| JP6342886B2 (ja) | 2012-04-18 | 2018-06-13 | ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアThe Children’S Hospital Of Philadelphia | Aavカプシドバリアントを使用した高効率な遺伝子導入のための組成物及び方法 |
| US9738879B2 (en) | 2012-04-27 | 2017-08-22 | Duke University | Genetic correction of mutated genes |
| WO2014043131A1 (en) | 2012-09-14 | 2014-03-20 | The Regents Of The University Of California | Lentiviral vector for stem cell gene therapy of sickle cell disease |
| US9181535B2 (en) | 2012-09-24 | 2015-11-10 | The Chinese University Of Hong Kong | Transcription activator-like effector nucleases (TALENs) |
| US9624510B2 (en) | 2013-03-01 | 2017-04-18 | The Wistar Institute | Adenoviral vectors comprising partial deletions of E3 |
| WO2014141244A1 (en) | 2013-03-12 | 2014-09-18 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Synthetic peptides for the treatment of autoimmune diseases |
| BR112015026019A2 (pt) | 2013-04-11 | 2017-07-25 | Brigham & Womens Hospital Inc | métodos e composições de tratamento de doenças autoimunes |
| US9873907B2 (en) | 2013-05-29 | 2018-01-23 | Agilent Technologies, Inc. | Method for fragmenting genomic DNA using CAS9 |
| US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
| US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
| US20150166984A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting alpha-antitrypsin point mutations |
| WO2015089443A2 (en) | 2013-12-12 | 2015-06-18 | The Brigham And Women's Hospital, Inc. | Treating neurodegenerative disease |
| US20160060358A1 (en) * | 2014-08-28 | 2016-03-03 | California Institute Of Technology | Induction of antigen-specific tolerance |
| EP3188749A4 (en) * | 2014-09-03 | 2018-06-13 | Moderna Therapeutics, Inc. | Tolerogenic compositions and methods |
| US10555919B2 (en) | 2014-11-12 | 2020-02-11 | The Brigham And Women's Hospital, Inc. | Melatonin in autoimmune disease |
| EP3274053A4 (en) * | 2015-03-23 | 2018-12-05 | The Brigham and Women's Hospital, Inc. | Tolerogenic nanoparticles for treating diabetes mellitus |
| GB201506112D0 (en) | 2015-04-10 | 2015-05-27 | Midatech Ltd And Inst Nationale De La Sant� Et De Al Rech Medicale And University College Car | Nanoparticle-based antigen specific immunotherapy |
| WO2016168670A2 (en) | 2015-04-16 | 2016-10-20 | Longevica Therapeutics Inc. | Methods for extending lifespan and methods of screening known pharmacological agents for new uses |
| EP3095440B1 (en) * | 2015-05-19 | 2020-01-15 | PLS-Design GmbH | Antigen-specific immunotherapy using tolerizing liposomes |
| US20170121683A1 (en) | 2015-11-03 | 2017-05-04 | Regents Of The University Of Minnesota | Aryl hydrocarbon receptor disruption and enhancement |
| WO2019099977A2 (en) | 2017-11-20 | 2019-05-23 | Ariagen, Inc. | Indole compounds and their use |
| JP2021515037A (ja) | 2018-02-26 | 2021-06-17 | アントルクス,インコーポレーテッド | 寛容原性リポソーム及びその使用方法 |
| TW202038943A (zh) | 2018-11-19 | 2020-11-01 | 美商雅里俊公司 | 治療癌症之方法 |
-
2019
- 2019-02-26 JP JP2020567462A patent/JP2021515037A/ja not_active Ceased
- 2019-02-26 AU AU2019225251A patent/AU2019225251A1/en not_active Abandoned
- 2019-02-26 EP EP19758300.8A patent/EP3758682A4/en not_active Withdrawn
- 2019-02-26 US US16/975,789 patent/US12178908B2/en active Active
- 2019-02-26 IL IL276957A patent/IL276957B2/en unknown
- 2019-02-26 KR KR1020207027609A patent/KR20200139679A/ko not_active Ceased
- 2019-02-26 WO PCT/US2019/019609 patent/WO2019165436A1/en not_active Ceased
- 2019-02-26 CN CN201980027908.2A patent/CN112384204B/zh not_active Expired - Fee Related
- 2019-02-26 CA CA3092372A patent/CA3092372A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019165436A1 (en) | 2019-08-29 |
| EP3758682A1 (en) | 2021-01-06 |
| IL276957A (en) | 2020-10-29 |
| IL276957B1 (en) | 2023-08-01 |
| CN112384204B (zh) | 2023-03-14 |
| US20200405642A1 (en) | 2020-12-31 |
| KR20200139679A (ko) | 2020-12-14 |
| US12178908B2 (en) | 2024-12-31 |
| JP2021515037A (ja) | 2021-06-17 |
| EP3758682A4 (en) | 2021-12-15 |
| IL276957B2 (en) | 2023-12-01 |
| CN112384204A (zh) | 2021-02-19 |
| AU2019225251A1 (en) | 2020-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12178908B2 (en) | Tolerogenic liposomes and methods of use thereof | |
| JP7427584B2 (ja) | 抗ウイルス導入ベクターigm応答を減弱化するための方法および組成物 | |
| US20230364124A1 (en) | Methods and compositions for attenuating anti-viral transfer vector immune responses | |
| AU2026202160A1 (en) | Delivery, use and therapeutic applications of the CRISPR-Cas systems and compositions for genome editing | |
| US20200390718A1 (en) | Methods and compositions for attenuated anti-viral transfer vector immune response | |
| EP4640835A1 (en) | Fusion and use thereof | |
| US20230141563A1 (en) | Methods and compositions for attenuating anti-viral transfer vector igm responses | |
| US20230357437A1 (en) | Immunosuppressants in combination with anti-igm agents and related dosing | |
| US20220387398A1 (en) | Immune tolerization agents and potentiators | |
| Saberi et al. | CRISPR/Cas system: a powerful strategy to improve monogenic human diseases as therapeutic delivery; current applications and challenges | |
| CN116656704A (zh) | 用于治疗法布里病的转基因表达盒 | |
| Xia et al. | Advances in Cystic Fibrosis Gene Therapy. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220929 |
|
| B12 | Application deemed to be withdrawn, abandoned or lapsed |
Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION Effective date: 20240829 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250904 |
|
| U13 | Renewal or maintenance fee not paid |
Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE Effective date: 20251104 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251229 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260427 |